Please login to the form below

Not currently logged in
Email:
Password:

fulranumab

This page shows the latest fulranumab news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Teva close gap on rivals with NGF pain drug

Regeneron and Teva close gap on rivals with NGF pain drug

was also developing an NGF inhibitor called fulranumab – formerly partnered with Johnson &Johnson and Takeda – but the collaborators handed back rights in 2016 and the drug  no longer features in

Latest news

  • FDA fast-tracks Pfizer and Lilly's tanezumab FDA fast-tracks Pfizer and Lilly's tanezumab

    One competitor - Amgen - has been developing its own candidate called fulranumab, but former partners Johnson &Johnson and Takeda handed back rights to the project last year.

  • FDA halts study of Teva and Regeneron's pain drug fasinumab FDA halts study of Teva and Regeneron's pain drug fasinumab

    Earlier this year, prospects for one of the most advanced candidates - Amgen's fulranumab - took a dive after licensees Johnson &Johnson and Takeda both decided to hand back rights, although they

  • Takeda hands back rights to two Amgen drugs Takeda hands back rights to two Amgen drugs

    However, Takeda has decided it is no longer interested in developing pain candidate fulranumab (AMG403) and trebananib (AMG386), which is being tested in cancer. ... J&J insisted that its decision to drop out of the fulranumab partnership stemmed from

  • Regeneron says anti-NGF fasinumab works in pain Regeneron says anti-NGF fasinumab works in pain

    A few weeks ago Johnson &Johnson (J&J) returned rights to its fulranumab candidate to originator company Amgen, despite the drug already being in multiple phase III trials.

  • J&J drops NGF blocker fulranumab J&J drops NGF blocker fulranumab

    Johnson &Johnson has returned the rights to fulranumab to Amgen, raising another question mark over the role of nerve growth factor (NGF) blockers as pain therapies. ... Last year, J&J chief executive Alex Gorsky listed fulranumab among 10 planned

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics